Tonix Pharmaceuticals to Present at the 2022 ThinkEquity Conference
CHATHAM, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today...
Vaccine
Gritstone to Host Data Update on CORAL and Discuss the Application of Self-amplifying mRNA (samRNA) in Infectious Diseases
-- Data to be presented from CORAL-BOOST and CORAL-CEPI trials evaluating Gritstone’s samRNA vaccine candidates against SARS-CoV-2 -- EMERYVILLE, Calif.,...
SteraMist to be Used in a Global Influenza Vaccine Facility in Australia
Company Continues To See Strong Bookings and A Robust Pipeline For Its Custom Engineered Systems in The Life Science SectorFREDERICK,...
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent...
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023SOUTH SAN FRANCISCO, Calif., Oct. 18,...
Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 without the Need for a Ritonavir Booster
Phase 1 Study (with 58 healthy volunteers) of STI-1558 was completed in Australia with 300 mg, 600 mg, 1,200 mg...
Bavarian Nordic Enters Agreement with Switzerland on the Supply of Smallpox and Monkeypox Vaccine
Switzerland has ordered 100,000 doses of smallpox and monkeypox vaccine with deliveries starting imminentlyBavarian Nordic will seek regulatory approval of...
Ramsay Sante : Annual results at the end of June 2022
PRESS RELEASE Paris, October 13th, 2022 Annual results at end June 2022 The solid performance of the Nordic countries has...
Altamira Therapeutics to Participate at RNA Leaders USA Congress
HAMILTON, BERMUDA , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Event will be held on October 18-19, 2022 in Boston, MASamuel...
GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
Data show overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above,...
Veru to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022
BOTHELL, Wash., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam...
Teknova Announces Early Access Program for Novel Products to Address Critical Pain Points in Gene Therapy Bioproduction
Company Also Announces New WFI Quality Water Product to be Made Available Through Online Catalog in NovemberHOLLISTER, Calif., Oct. 13,...
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
Study provides support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trialsBOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE)...
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
Sera collected from participants 7 days after administration of a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine...
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
• No safety concerns noted in ongoing clinical trial• Study timeline remains on track MALVERN, Pa., Oct. 12, 2022 (GLOBE...
Codex DNA Announces Plan to Change Corporate Name to Telesis Bio
Novel name reflects expansion of capabilities and solutionsSAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY),...
Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.
Estimated Over 1.4 Million Americans Suffer from LBD – Often Misdiagnosed – No Approved TreatmentsPURCHASE, N.Y., Oct. 12, 2022 (GLOBE...
Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses
– Data support advancement of Codiak’s engineered exosome bivalent vaccine candidate toward IND-enabling studies – CAMBRIDGE, Mass., Oct. 12, 2022...
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
Randomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022Study expected to assess VBI-1901...